Welcome to Arrien Pharmaceuticals
Arrien Pharmaceuticals is a clinical stage drug discovery company focused on developing small molecules targeting protein kinase signaling, nuclear hormone receptor and immuno-oncology/checkpoint pathway targets for treating human cancers, autoimmune and neurodegenerative diseases.
The company successfully applied its proprietary platform "FIELDS" technology and discovered two clinical candidates and others in development:
- ARN-6039 (currently known as BOS-172767), an orally available, selective small molecule inhibitor of ROR-γt (retinoic acid-related orphan nuclear hormone receptor gamma-t) being investigated in a Phase 1 clinical trials. The progress of ARN-6039 into Phase 1 development marks the milestone of Arrien Pharmaceuticals into a clinical stage organization. ARN-6039 was partnered with Boston Pharmaceuticals in 2017. A Phase 2 clinical POC studies in psoriasis and other autoimmune indications planed for Q1 2021. Our partner Boston Pharmaceuticals advancing several of their compounds in clinical trials that were the outcome of discovery collaborations and the responsibility for developing ARN-6039/BOS-172767 is with our partner.
- ARN-3261, an orally available small molecule inhibitor of SIK2 (Salt Inducible Kinase 2) to be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. ARN-3261 (now called GRN300) Licensed. Phase 1a/1b trials will be initiated in Q1 2021.
- ARN-0953, an orally available, highly selective small molecule inhibitor of the MELK (Maternal Embryonic Leucine Zipper Kinase) and FLT3/CD135 (FMS like Tyrosine Kinase 3) specific kinases. ARN-0953 currently in IND enabling studies and to be investigated in Phase 1 clinical trials for AML and other solid tumors (TNBC, GBM & Lung cancers).
Arrien Pharmaceuticals competitive and unique drug discovery and development approaches coupled with experienced scientific, clinical and business team who are expertise in multidisciplinary areas of kinase signaling, nuclear hormone receptor and checkpoint pathways and technology has been the key to company's success since its incorporation in 2011.
Our Pipeline
Our Small Molecule I-O Programs - Stages of Development

Our Non-Oncology Programs - Available for Partnering/Licensing

Our Partnered Program

Therapeutic Areas
Oncology Programs
Other Programes
